|
Malignant neoplasm of stomach
|
0.660 |
Biomarker
|
disease |
BEFREE |
MTMR2 mediated EMT through the IFNγ/STAT1/IRF1 pathway to promote GC invasion and metastasis.
|
31113461 |
2019 |
|
Malignant neoplasm of stomach
|
0.660 |
Biomarker
|
disease |
BEFREE |
These results suggest that the loss of functional IRF-1 is critical for the development of human gastric cancers.
|
9679752 |
1998 |
|
Malignant neoplasm of stomach
|
0.660 |
Biomarker
|
disease |
BEFREE |
We used these clones and recombinant adenovirus expressing IRF-1 to explore the mechanism of IRF-1-induced apoptosis in gastric cancer.
|
19851330 |
2010 |
|
Malignant neoplasm of stomach
|
0.660 |
GeneticVariation
|
disease |
BEFREE |
SNP rs56288038 (C/G) in IRF-1 3'UTR was involved in the occurrence of GC by acting as a tumor promoter factor.
|
27866197 |
2016 |
|
Malignant neoplasm of stomach
|
0.660 |
Biomarker
|
disease |
BEFREE |
MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling.
|
31186404 |
2019 |
|
Malignant neoplasm of stomach
|
0.660 |
GeneticVariation
|
disease |
BEFREE |
The interferon regulatory factor-1 (IRF1) gene, localized on chromosome 5q31.1, is mutated or rearranged in several cancers including some hematopoietic and gastric cancers.
|
19697121 |
2010 |
|
Stomach Carcinoma
|
0.650 |
Biomarker
|
disease |
BEFREE |
MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling.
|
31186404 |
2019 |
|
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
BEFREE |
Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer.
|
9679752 |
1998 |
|
Stomach Carcinoma
|
0.650 |
Biomarker
|
disease |
BEFREE |
We used these clones and recombinant adenovirus expressing IRF-1 to explore the mechanism of IRF-1-induced apoptosis in gastric cancer.
|
19851330 |
2010 |
|
Stomach Carcinoma
|
0.650 |
Biomarker
|
disease |
BEFREE |
MTMR2 mediated EMT through the IFNγ/STAT1/IRF1 pathway to promote GC invasion and metastasis.
|
31113461 |
2019 |
|
Stomach Carcinoma
|
0.650 |
GeneticVariation
|
disease |
BEFREE |
SNP rs56288038 (C/G) in IRF-1 3'UTR was involved in the occurrence of GC by acting as a tumor promoter factor.
|
27866197 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
Specific DNA protein complex formation was observed with the probes from the beta-casein and IRF-1 gene promoters, but not with the ISRE oligonucleotide probe, when cell extracts from acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) were investigated.
|
8634413 |
1996 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
Of approximately 1400 genes analyzed, 2 tumor-suppressor genes were identified that were overexpressed in all 7 of the AML CD34(+)/CD38(-) cell populations: death-associated protein kinase and interferon regulatory factor 1.
|
11264190 |
2001 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Involved in regulation of differentiation and proliferation, IRF-1 acts as a tumor suppressor gene and is inactivated by deletion of its one or more exons (exon skipping) in many hematological malignancies, including acute myelocytic leukemia (AML) and myelodysplastic syndromes (MDS).
|
21790247 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Thus, accelerated exon skipping results in a loss of IRF-1 expression and function that cannot be overcome by exposure to inducing agents in a subset of AML patients with -5/del(5q) and in APL.
|
10602416 |
1999 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
Biomarker
|
disease |
BEFREE |
The skipping of exons 2 or 2 and 3 of IRF-1 in patients with myelodysplastic syndromes and acute myelogenous leukaemia suggests that this factor may have a critical role in leukaemogenesis.
|
12358902 |
2002 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Clinically, approximately 70% of cases of acute myeloid leukaemia demonstrate dysregulated expression of IRF1 and/or IRF2.
|
18575764 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
We have investigated the allelic loss of IRF1 in a group of 12 patients with MDS and a 5q deletion and 2 patients with AML and a 5q deletion.
|
8219215 |
1993 |
|
Leukemia, Myelocytic, Acute
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Alterations in IRF1/IRF2 expression in acute myelogenous leukemia.
|
11559933 |
2001 |
|
Malignant neoplasm of lung
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we found that metformin depressed YAP promoter by competing with the binding of the transcription factor IRF-1 in lung cancer cells.
|
30389502 |
2018 |
|
Carcinoma of lung
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, we found that metformin depressed YAP promoter by competing with the binding of the transcription factor IRF-1 in lung cancer cells.
|
30389502 |
2018 |
|
Respiratory Syncytial Virus Infections
|
0.210 |
Biomarker
|
group |
BEFREE |
These observations suggest that RSV infection of human respiratory epithelial cells induces the iNOS gene both in vitro and in vivo; this induction may occur rather promptly and involves transcriptional activator IRF-1 induced by the RSV infection itself.
|
10410996 |
1999 |
|
Non-Small Cell Lung Carcinoma
|
0.120 |
Biomarker
|
disease |
BEFREE |
To examine genetic defects of the IFNγ-IRF1 pathway in non-small cell lung cancer (NSCLC), we analyzed The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LuAd) and lung squamous cell carcinoma (LuSc) data.
|
28977839 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.120 |
Biomarker
|
disease |
BEFREE |
The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC.
|
30389502 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, this identification of IRF1 as a dual regulator of BV6-induced apoptosis and inflammatory cytokine secretion provides novel insights into determinants of sensitivity towards Smac mimetic and possible implications of Smac mimetic treatment on tumor microenvironment and immune response.
|
25501823 |
2014 |